Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Inadequately Controlled Acromegaly
NCT02354508Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of pasireotide LAR in acromegaly, sponsored by Novartis. Primary endpoint: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at 36 weeks. Started Mar 2015; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT02354508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354508.